View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Deals Analysis
March 24, 2021

Medical Devices industry cross border deals total $545.3m globally in February 2021

Total medical devices industry cross border deals worth $545.3m were announced globally for February 2021, with the $108m private equity deal with Mainstay Medical International being the sector’s biggest investment, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 83.9% over the previous month of $3.38bn and a drop of 80.9% when compared with the last 12-month average of $2.86bn.

In terms of number of cross border deals, the sector saw a drop of 7.69% with 36 deals in February 2021 when compared to the last 12-month average of 39 deals.

In value terms, North America led the activity with cross border deals worth $305.47m in February 2021.

Medical Devices industry cross border deals in February 2021: Top deals

The top five cross border deals accounted for 66.1% of the overall value during February 2021.

The combined value of the top five cross border deals stood at $360.67m, against the overall value of $545.3m recorded for the month.

The top five medical devices industry cross border deals of February 2021 tracked by GlobalData were:

1) Ally Bridge Group, Fountain Healthcare Partners, KCK Group and Sofinnova Partners’ $108m private equity deal with Mainstay Medical International

2) The $90m venture financing of Hyperfine Research by Altium Capital, Axiom Associates, Colle Capital Partners, GV Management Co, Huamin Investment Management and Nextrans

3) Ally Bridge Group and Northpond Ventures’ $68m venture financing of Syapse

4) The $54.67m private equity deal of MaxCyte by ArrowMark Partners, Baron Capital Management, Casdin Capital, D1 Capital Partners, First Light Asset Management, Sofinnova Partners and T. Rowe Price Group

5) Orbimed Advisors and WuXi Huiying Investment’s venture financing deal with Guangzhou Benchmark Medical for $40m.

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network